. 2020 Aug 4;9(8):2509. doi: 10.3390/jcm9082509

Table 3.

Relationship between the levels of microRNAs in tumor tissue and clinicopathological characteristics.

			Target MicroRNAs
			MIR21		MIR29a		MIR92a
			−∆Ct value ^‡	p-value	−∆Ct value^‡	p-value	−∆Ct value ^‡	p-value
Gender	Male	17 (38.6)	2.58 (1.51–5.91)	0.87	0.92 (−0.16–3.5)	0.25	1.04 (−0.56–2.07)	0.41
Gender	Female	27 (61.4)	2.57 (1.55–4.86)	0.87	1.36 (−0.44–5.75)	0.25	1.01 (−0.82–3.87)	0.41
Age	≥75	14 (31.8)	2.30 (1.51–5.91)	0.66	1.42 (−0.44–5.75)	0.54	0.75 (−0.44–3.55)	0.82
Age	<75	30 (68.2)	2.61 (1.55–4.86)	0.66	1.17 (−0.14–2.50)	0.54	1.04 (−0.82–3.87)	0.82
BMI	≥22	22 (50.0)	2.48 (1.55–3.87)	0.03^*	0.4 (−0.17–2.50)	0.09†	0.75 (−0.82–2.41)	0.28
BMI	<22	22 (50.0)	2.96 (1.51–5.91)	0.03^*	1.62 (−0.44–5.75)	0.09†	1.10 (−0.44–3.87)	0.28
Tumor location	Colon	27 (61.4)	2.67 (1.51–5.91)	0.70	1.14 (−0.44–3.5)	0.47	0.71 (−0.82–2.79)	0.25
	Rectum	17 (38.6)	2.53 (1.55–4.86)	0.70	1.32 (−0.16–5.75)	0.47	1.12 (−0.56–3.87)	0.25
	Right side	17 (38.6)	2.52 (1.51–4.1)	0.16	0.84 (−0.44–2.19)	0.06†	0.68 (−0.82–2.41)	0.11
	Left side	27 (61.4)	2.65 (1.55–5.91)	0.16	1.36 (−0.16–5.75)	0.06†	1.12 (−0.56–3.87)	0.11
Preoperative CEA	Elevated	18 (40.1)	2.57 (1.55–5.91)	0.87	1.21 (−0.44–5.75)	0.64	1.04 (−0.82–3.55)	0.57
Preoperative CEA	Normal	26 (59.1)	2.61 (1.51–4.86)	0.87	1.27 (−0.17–2.5)	0.64	0.86 (−0.56–3.87)	0.57
Preoperative CA19-9	Elevated	12 (27.3)	2.54 (1.55–3.13)	0.14	1.01 (−0.16–2.05)	0.21	1.10 (−0.82–1.56)	0.07 †
Preoperative CA19-9	Normal	32 (72.7)	2.62 (1.51–5.91)	0.14	1.36 (−0.44–5.75)	0.21	1.08 (−0.56–3.78)	0.07 †
Maximum tumor diameter	≥45	22 (50.0)	2.57 (1.51–5.91)	0.95	1.34 (−0.17–3.5)	0.97	0.75 (−0.56–2.07)	0.16
Maximum tumor diameter	<45	22 (50.0)	2.65 (1.84–4.86)	0.95	1.04 (−0.44–5.75)	0.97	1.07 (−0.82–3.87)	0.16
Pathological T stage ^§	T3 + T4	33 (75.0)	2.67 (1.51–5.91)	0.77	1.14 (−0.44–5.75)	0.79	0.78 (−0.82–3.55)	0.51
Pathological T stage ^§	T1 + T2	11 (25.0)	2.57 (1.84–4.86)	0.77	1.28 (0.43–1.99)	0.79	1.07 (−0.56–3.87)	0.51
Pathological N stage ^§	Present	20 (45.4)	2.53 (1.51–5.91)	0.35	1.23 (−0.16–3.5)	0.57	0.64 (−0.82–1.87)	0.01 *
Pathological N stage ^§	Absent	24 (54.5)	2.67 (1.84–4.86)	0.35	1.24 (−0.44–5.75)	0.57	1.06 (−0.44–3.87)	0.01 *
Pathological Stage ^§	III + IV	22 (50.0)	2.53 (1.51- 5.91)	0.55	1.44 (−0.16–3.50)	0.85	0.86 (−0.82–1.92)	0.04 *
Pathological Stage ^§	I + II	22 (50.0)	2.665 (1.84–4.86)	0.55	1.12 (−0.44–5.75)	0.85	1.03 (−0.44–3.87)	0.04 *
Histological differentiation ^¶	Poorly	6 (13.6)	2.23 (1.51–2.83)	0.03*	0.6 (−0.16–1.92)	0.16	0.13 (−0.56–1.38)	0.03 *
Histological differentiation ^¶	Well and moderately	38 (86.4)	2.66 (1.84–5.91)	0.03*	1.32 (−0.44–5.75)	0.16	1.06 (−0.82–3.87)	0.03 *
Lymphatic invasion ^¶	High	13 (29.5)	2.53 (1.51–3.24)	0.14	0.84 (−0.17–2.05)	0.13	0.6 (−0.82–1.46)	0.02 *
Lymphatic invasion ^¶	Mild	31 (70.4)	2.65 (1.55–5.91)	0.14	1.35 (−0.44–5.75)	0.13	1.08 (−0.44–3.87)	0.02 *
Venous invasion ^¶	High	15 (34.1)	2.83 (2.14–5.91)	0.29	1.55 (−0.17–3.5)	0.33	1.12 (−0.56–1.87)	0.97
Venous invasion ^¶	Mild	29(65.9)	2.52 (1.51–4.86)	0.29	1.04 (−0.44–5.75)	0.33	0.71 (−0.82–3.87)	0.97
Perineural invasion ^¶	Positive	25 (56.8)	2.68 (1.51–5.91)	0.97	1.35 (−0.44–3.5)	0.97	1.04 (−0.44–2.41)	0.61
Perineural invasion ^¶	Negative	19 (43.2)	2.58 (1.84–4.86)	0.97	1.01 (0.2–5.75)	0.97	0.71(−0.82–3.87)	0.61

CEA: Carcinoembryonic antigen level, normal upper limit at 5 ng/mL, CA19-9: Carbohydrate antigen 19-9 level, normal upper limit at 37 ng/mL, ‡: −∆Ct value = −(Ct value (target MIR)–Ct value (internal control MIR16)), §: UICC TNM classification (the 8th edition), ¶: the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3rd English Edition (†: p < 0.1 *: p < 0.05).